NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'amico, Thomas Dilling, Michael Dobelbower, Ramaswamy Govindan, Mark Hennon, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Rudy P Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules LinBilly W. Loo, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Neelesh Sharma, Scott J. Swanson, James Stevenson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, Miranda Hughes

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

Original languageEnglish (US)
Pages (from-to)825-836
Number of pages12
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Guidelines
Pemetrexed
Cisplatin
Therapeutics
Malignant Mesothelioma
Neoplasm Metastasis
Recurrence
Bevacizumab

ASJC Scopus subject areas

  • Oncology

Cite this

Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., ... Hughes, M. (2016). NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016. JNCCN Journal of the National Comprehensive Cancer Network, 14(7), 825-836. https://doi.org/10.6004/jnccn.2016.0087

NCCN Guidelines® : Insights malignant pleural mesothelioma, version 3.2016. / Ettinger, David S.; Wood, Douglas E.; Akerley, Wallace; Bazhenova, Lyudmila A.; Borghaei, Hossein; Camidge, David Ross; Cheney, Richard T.; Chirieac, Lucian R.; D'amico, Thomas A.; Dilling, Thomas; Dobelbower, Michael; Govindan, Ramaswamy; Hennon, Mark; Horn, Leora; Jahan, Thierry M.; Komaki, Ritsuko; Lackner, Rudy P; Lanuti, Michael; Lilenbaum, Rogerio; Lin, Jules; Loo, Billy W.; Martins, Renato; Otterson, Gregory A.; Patel, Jyoti D.; Pisters, Katherine M.; Reckamp, Karen; Riely, Gregory J.; Schild, Steven E.; Shapiro, Theresa A.; Sharma, Neelesh; Swanson, Scott J.; Stevenson, James; Tauer, Kurt; Yang, Stephen C.; Gregory, Kristina; Hughes, Miranda.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, No. 7, 01.07.2016, p. 825-836.

Research output: Contribution to journalReview article

Ettinger, DS, Wood, DE, Akerley, W, Bazhenova, LA, Borghaei, H, Camidge, DR, Cheney, RT, Chirieac, LR, D'amico, TA, Dilling, T, Dobelbower, M, Govindan, R, Hennon, M, Horn, L, Jahan, TM, Komaki, R, Lackner, RP, Lanuti, M, Lilenbaum, R, Lin, J, Loo, BW, Martins, R, Otterson, GA, Patel, JD, Pisters, KM, Reckamp, K, Riely, GJ, Schild, SE, Shapiro, TA, Sharma, N, Swanson, SJ, Stevenson, J, Tauer, K, Yang, SC, Gregory, K & Hughes, M 2016, 'NCCN Guidelines®: Insights malignant pleural mesothelioma, version 3.2016', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 7, pp. 825-836. https://doi.org/10.6004/jnccn.2016.0087
Ettinger, David S. ; Wood, Douglas E. ; Akerley, Wallace ; Bazhenova, Lyudmila A. ; Borghaei, Hossein ; Camidge, David Ross ; Cheney, Richard T. ; Chirieac, Lucian R. ; D'amico, Thomas A. ; Dilling, Thomas ; Dobelbower, Michael ; Govindan, Ramaswamy ; Hennon, Mark ; Horn, Leora ; Jahan, Thierry M. ; Komaki, Ritsuko ; Lackner, Rudy P ; Lanuti, Michael ; Lilenbaum, Rogerio ; Lin, Jules ; Loo, Billy W. ; Martins, Renato ; Otterson, Gregory A. ; Patel, Jyoti D. ; Pisters, Katherine M. ; Reckamp, Karen ; Riely, Gregory J. ; Schild, Steven E. ; Shapiro, Theresa A. ; Sharma, Neelesh ; Swanson, Scott J. ; Stevenson, James ; Tauer, Kurt ; Yang, Stephen C. ; Gregory, Kristina ; Hughes, Miranda. / NCCN Guidelines® : Insights malignant pleural mesothelioma, version 3.2016. In: JNCCN Journal of the National Comprehensive Cancer Network. 2016 ; Vol. 14, No. 7. pp. 825-836.
@article{48012fcc1ec848e68aba8c5c0fb6e254,
title = "NCCN Guidelines{\circledR}: Insights malignant pleural mesothelioma, version 3.2016",
abstract = "These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.",
author = "Ettinger, {David S.} and Wood, {Douglas E.} and Wallace Akerley and Bazhenova, {Lyudmila A.} and Hossein Borghaei and Camidge, {David Ross} and Cheney, {Richard T.} and Chirieac, {Lucian R.} and D'amico, {Thomas A.} and Thomas Dilling and Michael Dobelbower and Ramaswamy Govindan and Mark Hennon and Leora Horn and Jahan, {Thierry M.} and Ritsuko Komaki and Lackner, {Rudy P} and Michael Lanuti and Rogerio Lilenbaum and Jules Lin and Loo, {Billy W.} and Renato Martins and Otterson, {Gregory A.} and Patel, {Jyoti D.} and Pisters, {Katherine M.} and Karen Reckamp and Riely, {Gregory J.} and Schild, {Steven E.} and Shapiro, {Theresa A.} and Neelesh Sharma and Swanson, {Scott J.} and James Stevenson and Kurt Tauer and Yang, {Stephen C.} and Kristina Gregory and Miranda Hughes",
year = "2016",
month = "7",
day = "1",
doi = "10.6004/jnccn.2016.0087",
language = "English (US)",
volume = "14",
pages = "825--836",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - NCCN Guidelines®

T2 - Insights malignant pleural mesothelioma, version 3.2016

AU - Ettinger, David S.

AU - Wood, Douglas E.

AU - Akerley, Wallace

AU - Bazhenova, Lyudmila A.

AU - Borghaei, Hossein

AU - Camidge, David Ross

AU - Cheney, Richard T.

AU - Chirieac, Lucian R.

AU - D'amico, Thomas A.

AU - Dilling, Thomas

AU - Dobelbower, Michael

AU - Govindan, Ramaswamy

AU - Hennon, Mark

AU - Horn, Leora

AU - Jahan, Thierry M.

AU - Komaki, Ritsuko

AU - Lackner, Rudy P

AU - Lanuti, Michael

AU - Lilenbaum, Rogerio

AU - Lin, Jules

AU - Loo, Billy W.

AU - Martins, Renato

AU - Otterson, Gregory A.

AU - Patel, Jyoti D.

AU - Pisters, Katherine M.

AU - Reckamp, Karen

AU - Riely, Gregory J.

AU - Schild, Steven E.

AU - Shapiro, Theresa A.

AU - Sharma, Neelesh

AU - Swanson, Scott J.

AU - Stevenson, James

AU - Tauer, Kurt

AU - Yang, Stephen C.

AU - Gregory, Kristina

AU - Hughes, Miranda

PY - 2016/7/1

Y1 - 2016/7/1

N2 - These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

AB - These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

UR - http://www.scopus.com/inward/record.url?scp=84978806340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978806340&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2016.0087

DO - 10.6004/jnccn.2016.0087

M3 - Review article

C2 - 27407123

AN - SCOPUS:84978806340

VL - 14

SP - 825

EP - 836

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 7

ER -